The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A07 | Antidiarrheals, intestinal antiinflammatory/antiinfective agents | |
| 3 | A07E | Intestinal antiinflammatory agents | |
| 4 | A07EC | Aminosalicylic acid and similar agents | |
| 5 | A07EC01 | Sulfasalazine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2 g |
| RECTAL - Rectal | 2 g |
| Active Ingredient | Description | |
|---|---|---|
| Sulfasalazine |
Therapeutic benefit of sulfasalazine appears to be due to a local action of the sulfasalazine and its split product 5-aminosalicylic acid on the mucous membrane and deeper colonic structures. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AZULFIDINE Tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| SALAZOPYRIN Suppository | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
